(Q44153140)

English

Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum

scientific article published on August 4, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

phase I clinical trial

0 references

Plasmodium falciparum

0 references

0 references

malaria vaccine

1 reference

based on heuristic

inferred from title

1

object named as

Blaise Genton

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Robert Sauerwein

10

object named as

Robert Sauerwein

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Cornelus C Hermsen

6

object named as

Cornelus Hermsen

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

Valérie D'Acremont

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Floriana Lurati-Ruiz

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Daniele Verhage

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Régine Audran

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Liselotte Wolters

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Christophe Reymond

8

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

François Spertini

9

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Cornelus Hermsen

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20691266

18 June 2024

language of work or name

0 references

publication date

4 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0264410X10010789?httpAccept=text/xml

1 reference

10.1016/J.VACCINE.2010.07.067

https://api.crossref.org/works/10.1016/J.VACCINE.2010.07.067

18 June 2024

https://api.elsevier.com/content/article/PII:S0264410X10010789?httpAccept=text/plain

1 reference

10.1016/J.VACCINE.2010.07.067

https://api.crossref.org/works/10.1016/J.VACCINE.2010.07.067

18 June 2024

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

40

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

6573-6580

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Malaria vaccines: a toy for travelers or a tool for eradication?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Malaria vaccines and their potential role in the elimination of malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Pre-erythrocytic stage malaria vaccines: time for a change in path

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Pre-erythrocytic malaria vaccines: towards greater efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Peptide based malaria vaccine development: personal considerations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

The synthetic, oxidized C-terminal fragment of the Plasmodium berghei circumsporozoite protein elicits a high protective response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

The dog that did not bark: malaria vaccines without antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Human challenge studies with infectious agents

23

1 reference

10.1016/J.VACCINE.2010.07.067

https://api.crossref.org/works/10.1016/J.VACCINE.2010.07.067

18 June 2024

Malaria vaccines: are we getting closer?

24

1 reference

10.1016/J.VACCINE.2010.07.067

https://api.crossref.org/works/10.1016/J.VACCINE.2010.07.067

18 June 2024

Identifiers

10.1016/J.VACCINE.2010.07.067

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

release_qwcpesfclrhulk3l2tjpg5p3si

1 reference

https://api.fatcat.wiki/v0/release/qwcpesfclrhulk3l2tjpg5p3si

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44153140&oldid=2182624593"